William G. Wierda

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

120h-index62.0kcitations1.5kworks3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(1168), Lymphoma Diagnosis and Treatment(521), Acute Lymphoblastic Leukemia research(316), Chronic Myeloid Leukemia Treatments(315), Immunodeficiency and Autoimmune Disorders(215)

Publications1.5k total

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Journal of Clinical Oncology·2025· 2 citedOpen Access
Supplementary Table S3 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
2025Open Access
Supplementary Tables S1-S3 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
2025Open Access
Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
2025Open Access
Supplementary Table S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
2025Open Access
Supplementary Methods S1 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
2025Open Access
Supplementary Figures S1-S4 from Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies
2025Open Access
Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
2025Open Access
Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia
Cancers·2025Open Access
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Blood Cancer Discovery·2025· 1 cited
Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia
Blood·2025
Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia
Blood·2025Open Access
Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial
Blood·2025
Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL
Blood·2025Open Access
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Blood·2025Open Access
Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion
Blood·2025Open Access
Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia
Blood·2025Open Access
A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia
Blood·2025
Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase
Blood·2025
Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study
Blood·2025Open Access
page 1 of 77Next →

Frequent Co-authors

Hagop M. Kantarjian(23), Michael J. Keating(18), Jörge E. Cortes(16), Guillermo Garcia‐Manero(15), Jan A. Burger(14), Susan O’Brien(14), Alessandra Ferrajoli(13), Stefan Faderl(12), Farhad Ravandi(11), Zeev Estrov(9), Steven Coutré(8), Susan O’Brien(8), Francis J. Giles(8), Richard R. Furman(7), Elias Jabbour(7), Nitin Jain(6), Jeffrey A. Jones(6), Matthew S. Davids(6), Thomas J. Kipps(6), Deborah A. Thomas(6)